Allianz Asset Management’s Travere Therapeutics TVTX Stock Holding History

Allianz Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	+42,966	New	+$1.9M	﹤0.01%	1674
2026 Q1	–	Sell	-5,500	Closed	-$210K	–	2108
2025 Q4	$210K	Buy	+5,500	New	+$179K	﹤0.01%	1933
2022 Q3	–	Sell	-109,513	Closed	-$2.65M	–	2128
2022 Q2	$2.65M	Buy	109,513 +45,793	+72%	+$1.15M	﹤0.01%	1317
2022 Q1	$1.64M	Buy	63,720 +3,900	+7%	+$104K	﹤0.01%	1669
2021 Q4	$1.85M	Buy	+59,820	New	+$1.68M	﹤0.01%	1645
2021 Q2	–	Sell	-14,635	Closed	-$365K	–	2485
2021 Q1	$365K	Sell	14,635 -68,985	-82%	-$1.91M	﹤0.01%	2007
2020 Q4	$2.28M	Buy	83,620 +13,507	+19%	+$315K	﹤0.01%	1276
2020 Q3	$1.29M	Sell	70,113 -6,463	-8%	-$126K	﹤0.01%	1368
2020 Q2	$1.56M	Buy	+76,576	New	+$1.22M	﹤0.01%	1702
2019 Q4	–	Sell	-34,646	Closed	-$407K	–	2843
2019 Q3	$407K	Buy	34,646 +8,540	+33%	+$141K	﹤0.01%	2439
2019 Q2	$525K	Sell	26,106 -1,669	-6%	-$33K	﹤0.01%	2330
2019 Q1	$628K	Buy	27,775 +2,625	+10%	+$58K	﹤0.01%	2250
2018 Q4	$566K	Buy	+25,150	New	+$626K	﹤0.01%	2231

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management's TVTX Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 42,966 shares worth $2.44M. The stake represents ﹤0.01% of the portfolio and ranks #1674 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in TVTX as recently as Q4 2025.

Allianz Asset Management first reported a position in TVTX in Q4 2018 and has held it in 13 quarters since. The position peaked at $2.65M in Q2 2022. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Allianz Asset Management held 42,966 shares of Travere Therapeutics worth $2.44M as of Q2 2026.
Travere Therapeutics was a new Allianz Asset Management position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1674 holding.
Allianz Asset Management first reported a position in Travere Therapeutics in Q4 2018 and has held it in 13 quarters since.
Allianz Asset Management's Travere Therapeutics position peaked at $2.65M in Q2 2022.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.